侵袭性垂体神经内分泌肿瘤:当前实践、争议与展望
侵袭性垂体神经内分泌肿瘤占垂体肿瘤的10%,其管理正转向神经肿瘤学模式。本文综述当前预后标志物(含五层级临床病理分类),并从神经外科视角提出四条推荐:手术及多阶段手术应各阶段讨论;替莫唑胺对多数患者有效但30%无应答;部分患者可早期局部放疗和/或化疗;VEGF靶向及免疫治疗作为二线或三线选择。
要点
- 手术及多阶段手术应贯穿疾病各阶段讨论,可能增强辅助药物治疗效果。
- 替莫唑胺对多数患者有效,但30%无应答,最佳起始和中断时机尚不明确。
- VEGF靶向治疗和抗CTLA-4/抗PD1免疫治疗有前景,应作为二线或三线讨论。
核心结论
- 侵袭性垂体神经内分泌肿瘤管理趋向神经肿瘤学模式,神经外科医生在各阶段均起关键作用。
研究设计与样本
- 叙述性综述,由EANS颅底分会组织,总结当前知识、争议和推荐。
主要发现
- 侵袭性垂体神经内分泌肿瘤占垂体肿瘤的10%。
- 替莫唑胺对多数患者有效,但30%患者无应答。
- VEGF靶向治疗和抗CTLA-4/抗PD1免疫治疗有前景。
关键数值与推荐
- 手术及多阶段手术(伴或不伴鞍旁切除)应在疾病各阶段讨论。
- 部分具有特定临床病理特征的患者可能受益于早期局部放疗和/或化疗。
- VEGF靶向治疗和抗CTLA-4/抗PD1免疫治疗应作为二线或三线治疗讨论。
临床怎么用
- 神经外科医生应在疾病各阶段评估手术及多阶段手术指征。
- 替莫唑胺治疗中需关注30%无应答者,并权衡最佳用药时机。
- 对特定临床病理特征患者可考虑早期局部放疗和/或化疗。
- 二线或三线治疗可讨论VEGF靶向治疗和免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary tumors. Their management is a rapidly evolving field of clinical research and has led pituitary teams to shift toward a neuro-oncological-like approach. The new terminology "Pituitary neuroendocrine tumors" (PitNet) that was recently proposed to replace "pituitary adenomas" reflects this change of paradigm. In this narrative review, we aim to provide a state of the art of actual knowledge, controversies, and recommendations in the management of APT. We propose an overview of current prognostic markers, including the recent five-tiered clinicopathological classification. We further establish and discuss the following recommendations from a neurosurgical perspective: (i) surgery and multi-staged surgeries (without or with parasellar resection in symptomatic patients) should be discussed at each stage of the disease, because it may potentialize adjuvant medical therapies; (ii) temozolomide is effective in most patients, although 30% of patients are non-responders and the optimal timeline to initiate and interrupt this treatment remains questionable; (iii) some patients with selected clinicopathological profiles may benefit from an earlier local radiotherapy and/or chemotherapy; (iv) novel therapies such as VEGF-targeted therapies and anti-CTLA-4/anti-PD1 immunotherapies are promising and should be discussed as 2nd or 3rd line of treatment. Finally, whether neurosurgeons have to operate on "pituitary adenomas" or "PitNets," their role and expertise remain crucial at each stage of the disease, prompting our community to deal with evolving concepts and therapeutic resources.
引用
- Ng S, Messerer M, Engelhardt J, et al. Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien). 2021. PMID: 34365544. doi:10.1007/s00701-021-04953-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。